Risperidone controlled-release implant - Braeburn PharmaceuticalsAlternative Names: BB0817; EN 3342
Latest Information Update: 17 May 2016
At a glance
- Originator Endo Pharmaceuticals
- Developer Braeburn Pharmaceuticals
- Class Antineoplastics; Antipsychotics; Isoxazoles; Piperidines; Pyrimidinones; Small molecules
- Mechanism of Action Dopamine D2 receptor antagonists; Serotonin 2A receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase III Schizophrenia